Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| ISRCTN45979711 | Other Identifier | International Standard Randomised Controlled Trial Number Register |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute for Health Research, United Kingdom | OTHER_GOV |
| London School of Hygiene and Tropical Medicine | OTHER |
| University of York | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will assess whether percutaneous coronary intervention (angioplasty of the heart arteries) can improve survival and reduce hospitalization in patients with heart failure due to coronary disease, who have been treated with the best contemporary medical therapy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Percutaneous Coronary Intervention and Optimal Medical Therapy | Experimental |
| |
| Optimal Medical Therapy alone | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Percutaneous Coronary Intervention | Procedure |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| All-cause death or Hospitalization for Heart Failure | This composite endpoint will be collected over the entire duration of follow-up in the trial when the last patient randomized has reached 2 years of follow-up post randomization | 1 to 103 months (min follow-up duration: 24 months) |
| Measure | Description | Time Frame |
|---|---|---|
| Left Ventricular Ejection Fraction | Left Ventricular Ejection Fraction (LVEF) on echocardiography | 6 months, 1 year |
| Quality of Life Scores | Kansas City Cardiomyopathy questionnaire (KCCQ) up to 2 years EuroQol EQ-5D-5L at 6 months and then yearly to the end of follow-up. |
| Measure | Description | Time Frame |
|---|---|---|
| NHS Resource Use | Health Economic Analysis | 1 to 103 months (min follow-up duration: 24 months) |
Inclusion Criteria:
ALL of the following:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Divaka Perera, MB BChir, MA, MD, FRCP | King's College London | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Basingstoke and North Hampshire Hospital | Basingstoke | RG24 9NA | United Kingdom | |||
| Royal Victoria Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40972554 | Derived | Ovesen C, Dodd M, Ryan M, Clayton T, Sharples L, Perera D. Impact of baseline risk of death or hospitalization on effectiveness of revascularization in patients with ischaemic left ventricular dysfunction-a prespecified analysis of REVIVED-BCIS2. Eur Heart J Qual Care Clin Outcomes. 2025 Dec 19;11(8):1440-1447. doi: 10.1093/ehjqcco/qcaf108. | |
| 38759904 |
Not provided
Not provided
Not provided
| Guy's and St Thomas' NHS Foundation Trust |
| OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug Therapy for Heart Failure | Drug | The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines |
|
| Device Therapy for Heart Failure | Device | The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy. |
|
| 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years |
| New York Heart Association Functional (NYHA) Class | 6 months, 1 year, 2 years |
| Cardiovascular Death | Cardiovascular death over the entire duration of follow-up | 1 to 103 months (min follow-up duration: 24 months) |
| All-cause death | All-cause death over the entire duration of follow-up | 1 to 103 months (min follow-up duration: 24 months) |
| Hospitalization due to heart failure | Hospitalization due to heart failure over the entire duration of follow-up | 1 to 103 months (min follow-up duration: 24 months) |
| Acute Myocardial Infarction | Acute myocardial infarction (MI) over the entire duration of follow-up | 1 to 103 months (min follow-up duration: 24 months) |
| Appropriate Implantable Cardioverter Defibrillator Therapy | Appropriate implantable cardioverter defibrillator (ICD) therapy to 2 years | 6 months, 1 year, 2 years |
| Unplanned further revascularization | Unplanned further revascularization over the entire duration of follow-up | 1 to 103 months (min follow-up duration: 24 months) |
| Canadian Cardiovascular Society class | Canadian Cardiovascular Society (CCS) class up to 2 years | 6 months, 1 year, 2 years |
| Brain-type Natriuretic Peptide level | Brain natriuretic peptide (BNP or NT-Pro BNP) up to 2 years | 6 months, 1 year, 2 years |
| Major Bleeding | Major bleeding up to 2 years | 6 months, 1 year, 2 years |
| Belfast |
| BT12 6BA |
| United Kingdom |
| Birmingham Heartlands Hospital | Birmingham | B9 5SS | United Kingdom |
| Blackpool Victoria Hospital | Blackpool | FY3 8NR | United Kingdom |
| North Wales Cardiac Centre | Bodelwyddan | LL18 5UJ | United Kingdom |
| Royal Bournemouth Hospital | Bournemouth | BH7 7DW | United Kingdom |
| Bristol Heart Institute | Bristol | BS2 8HW | United Kingdom |
| University Hospital Coventry | Coventry | CV2 2DX | United Kingdom |
| Dorset County Hospital | Dorchester | DT1 2JY | United Kingdom |
| Ninewells Hospital | Dundee | DD1 9SY | United Kingdom |
| Royal Infirmary of Edinburgh | Edinburgh | EH16 4SA | United Kingdom |
| Royal Devon and Exeter Hospital | Exeter | EX2 5DW | United Kingdom |
| Golden Jubilee National Hospital | Glasgow | G81 4DY | United Kingdom |
| Kettering General Hospital | Kettering | NN16 8UZ | United Kingdom |
| Leeds General Infirmary | Leeds | LS1 3EX | United Kingdom |
| Glenfield Hospital | Leicester | LE3 9QP | United Kingdom |
| Liverpool Heart and Chest Hospital | Liverpool | L14 3PE | United Kingdom |
| Barts Heart Centre | London | EC1A 7BE | United Kingdom |
| Royal Free Hospital | London | NW3 2QG | United Kingdom |
| Guy's and St Thomas' Hospital | London | SE1 7EH | United Kingdom |
| King's College Hospital | London | SE5 9RS | United Kingdom |
| St George's Hospital | London | SW17 0QT | United Kingdom |
| Manchester Royal Infirmary | Manchester | M13 9WL | United Kingdom |
| The James Cook University Hospital | Middlesbrough | TS4 3BW | United Kingdom |
| Freeman Hospital | Newcastle | NE7 7DN | United Kingdom |
| Royal Oldham Hospital | Oldham | OL1 2JH | United Kingdom |
| Derriford Hospital | Plymouth | PL6 8DH | United Kingdom |
| Queen Alexandra Hospital | Portsmouth | PO6 3LY | United Kingdom |
| Salisbury District Hospital | Salisbury | SP2 8BJ | United Kingdom |
| Northern General Hospital | Sheffield | S5 7AU | United Kingdom |
| Southampton General Hospital | Southampton | SO16 6YD | United Kingdom |
| Lister Hospital | Stevenage | SG1 4AB | United Kingdom |
| Sunderland Royal Hospital | Sunderland | SR4 7TP | United Kingdom |
| Great Western Hospital | Swindon | SN3 6BB | United Kingdom |
| Pinderfields Hospital | Wakefield | WF1 4DG | United Kingdom |
| New Cross Hospital | Wolverhampton | WV10 0QP | United Kingdom |
| Worcestershire Royal Hospital | Worcester | WR5 1DD | United Kingdom |
| Worthing Hospital | Worthing | BN11 2DH | United Kingdom |
| Wythenshawe Hospital | Wythenshawe | M23 9LT | United Kingdom |
| York Hospital | York | YO31 8HE | United Kingdom |
| Ezad SM, McEntegart M, Dodd M, Didagelos M, Sidik N, Li Kam Wa M, Morgan HP, Pavlidis A, Weerackody R, Walsh SJ, Spratt JC, Strange J, Ludman P, Chiribiri A, Clayton T, Petrie MC, O'Kane P, Perera D; REVIVED-BCIS2 Investigators. Impact of Anatomical and Viability-Guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy. J Am Coll Cardiol. 2024 Jul 23;84(4):340-350. doi: 10.1016/j.jacc.2024.04.043. Epub 2024 May 15. |
| 38727649 | Derived | Ryan M, Taylor D, Dodd M, Spertus JA, Kosiborod MN, Shaukat A, Docherty KF, Clayton T, Perera D, Petrie MC; REVIVED-BCIS2 Investigators. Effect of PCI on Health Status in Ischemic Left Ventricular Dysfunction: Insights From REVIVED-BCIS2. JACC Heart Fail. 2024 Sep;12(9):1553-1562. doi: 10.1016/j.jchf.2024.03.010. Epub 2024 Apr 8. |
| 37929587 | Derived | Chivardi C, Morgan H, Sculpher MJ, Clayton T, Evans R, Dodd M, Petrie M, Rinaldi CA, O'Kane P, Brown L, Perera D, Saramago P; REVIVED-BCIS2 Investigators. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction: Cost-Effectiveness Analysis of the REVIVED-BCIS2 Trial. Circ Cardiovasc Qual Outcomes. 2024 Jan;17(1):e010533. doi: 10.1161/CIRCOUTCOMES.123.010533. Epub 2023 Nov 6. |
| 37878295 | Derived | Perera D, Ryan M, Morgan HP, Greenwood JP, Petrie MC, Dodd M, Weerackody R, O'Kane PD, Masci PG, Nazir MS, Papachristidis A, Chahal N, Khattar R, Ezad SM, Kapetanakis S, Dixon LJ, De Silva K, McDiarmid AK, Marber MS, McDonagh T, McCann GP, Clayton TC, Senior R, Chiribiri A; REVIVED-BCIS2 Investigators. Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction: A Prespecified Secondary Analysis of the REVIVED-BCIS2 Trial. JAMA Cardiol. 2023 Dec 1;8(12):1154-1161. doi: 10.1001/jamacardio.2023.3803. |
| 37555345 | Derived | Perera D, Morgan HP, Ryan M, Dodd M, Clayton T, O'Kane PD, Greenwood JP, Walsh SJ, Weerackody R, McDiarmid A, Amin-Youssef G, Strange J, Modi B, Lockie T, Hogrefe K, Ahmed FZ, Behan M, Jenkins N, Abdelaal E, Anderson M, Watkins S, Evans R, Rinaldi CA, Petrie MC; REVIVED-BCIS2 Investigators. Arrhythmia and Death Following Percutaneous Revascularization in Ischemic Left Ventricular Dysfunction: Prespecified Analyses From the REVIVED-BCIS2 Trial. Circulation. 2023 Sep 12;148(11):862-871. doi: 10.1161/CIRCULATIONAHA.123.065300. Epub 2023 Aug 9. |
| 36741102 | Derived | Ezad SM, Ryan M, Perera D. Can Percutaneous Coronary Intervention Revive a Failing Heart? Heart Int. 2022 Dec 21;16(2):72-74. doi: 10.17925/HI.2022.16.2.72. eCollection 2022. |
| 36027563 | Derived | Perera D, Clayton T, O'Kane PD, Greenwood JP, Weerackody R, Ryan M, Morgan HP, Dodd M, Evans R, Canter R, Arnold S, Dixon LJ, Edwards RJ, De Silva K, Spratt JC, Conway D, Cotton J, McEntegart M, Chiribiri A, Saramago P, Gershlick A, Shah AM, Clark AL, Petrie MC; REVIVED-BCIS2 Investigators. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. N Engl J Med. 2022 Oct 13;387(15):1351-1360. doi: 10.1056/NEJMoa2206606. Epub 2022 Aug 27. |
| 29852933 | Derived | Perera D, Clayton T, Petrie MC, Greenwood JP, O'Kane PD, Evans R, Sculpher M, Mcdonagh T, Gershlick A, de Belder M, Redwood S, Carr-White G, Marber M; REVIVED investigators. Percutaneous Revascularization for Ischemic Ventricular Dysfunction: Rationale and Design of the REVIVED-BCIS2 Trial: Percutaneous Coronary Intervention for Ischemic Cardiomyopathy. JACC Heart Fail. 2018 Jun;6(6):517-526. doi: 10.1016/j.jchf.2018.01.024. |
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| D018754 | Ventricular Dysfunction |
| D017202 | Myocardial Ischemia |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D062645 | Percutaneous Coronary Intervention |
| D000800 | Angioplasty, Balloon |
| D015607 | Stents |
| D004358 | Drug Therapy |
| ID | Term |
|---|---|
| D057510 | Endovascular Procedures |
| D014656 | Vascular Surgical Procedures |
| D013504 | Cardiovascular Surgical Procedures |
| D013514 | Surgical Procedures, Operative |
| D019060 | Minimally Invasive Surgical Procedures |
| D017130 | Angioplasty |
| D002404 | Catheterization |
| D013812 | Therapeutics |
| D008919 | Investigative Techniques |
| D019736 | Prostheses and Implants |
| D004864 | Equipment and Supplies |
Not provided
Not provided